PHARMACEUTICAL COMPOSITION OF FABOMOTIZOLE DIHYDROCHLORIDE Russian patent published in 2024 - IPC A61K31/4184 A61K31/5375 A61K31/5377 A61K9/20 A61K47/12 A61K47/26 A61K47/36 A61K47/38 A61P25/22 

FIELD: medicine; pharmaceutical industry.

SUBSTANCE: invention relates to a solid pharmaceutical composition based on fabomotizole dihydrochloride, having anxiolytic activity, and can be used for the production of a drug in the form of tablets by direct compression. Disclosed pharmaceutical composition contains, wt.%: fabomotizole dihydrochloride 0.5–30; 2-mercapto-5-ethoxybenzimidazole 0.001–1 and/or 4-(2-chloroethyl)morpholine hydrochloride 0.0001–0.5; mannitol, and/or calcium hydrophosphate, and/or anhydrous lactose, and/or sorbitol, and/or maltodextrin, and/or lactose monohydrate, and/or microcrystalline cellulose, and/or silicated microcrystalline cellulose 68.8989–85; pregelated starch, and/or croscarmellose sodium, and/or sodium carboxymethyl starch, and/or crospovidone, and/or povidone, and/or copovidone, and/or low-substituted hyprolose, and/or hyprolose, and/or hydroxypropylmethylcellulose, and/or ethylcellulose, with the exception of potato starch or maize starch, 1.0–10; calcium stearate, and/or sodium stearyl fumarate, and/or stearic acid, and/or magnesium stearate, and/or hydrogenated castor oil, and/or silicon dioxide, and/or talc 0.1–3.

EFFECT: high efficiency of the technology of producing a solid pharmaceutical composition per unit time with simultaneous increase in the quality of the produced tablet forms, which are stable during the entire shelf life of the preparation.

2 cl, 2 tbl, 3 dwg, 4 ex